Prevalence and Overlap of Potential Embolic Sources in Patients With Embolic Stroke of Undetermined Source

Background We aimed to assess the prevalence and degree of overlap of potential embolic sources (PES) in patients with embolic stroke of undetermined source (ESUS). Methods and Results In a pooled data set derived from 3 prospective stroke registries, patients were categorized in ≥1 groups according to the PES that was/were identified. We categorized PES as follows: atrial cardiopathy, atrial fibrillation diagnosed during follow‐up, arterial disease, left ventricular disease, cardiac valvular disease, patent foramen ovale, and cancer. In 800 patients with ESUS (43.1% women; median age, 67.0 years), 3 most prevalent PES were left ventricular disease, arterial disease, and atrial cardiopathy, which were present in 54.4%, 48.5%, and 45.0% of patients, respectively. Most patients (65.5%) had >1 PES, whereas only 29.7% and 4.8% of patients had a single or no PES, respectively. In 31.1% of patients, there were ≥3 PES present. On average, each patient had 2 PES (median, 2). During a median follow‐up of 3.7 years, stroke recurrence occurred in 101 (12.6%) of patients (23.3 recurrences per 100 patient‐years). In multivariate analysis, the risk of stroke recurrence was higher in the atrial fibrillation group compared with other PES, but not statistically different between patients with 0 to 1, 2, or ≥3 PES. Conclusions There is major overlap of PES in patients with ESUS. This may possibly explain the negative results of the recent large randomized controlled trials of secondary prevention in patients with ESUS and offer a rationale for a randomized controlled trial of combination of anticoagulation and aspirin for the prevention of stroke recurrence in patients with ESUS. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT02766205.

[1]  G. Sirimarco,et al.  Carotid plaques and detection of atrial fibrillation in embolic stroke of undetermined source , 2019, Neurology.

[2]  R. Kronmal,et al.  The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods , 2018, International journal of stroke : official journal of the International Stroke Society.

[3]  P. Kirchhof,et al.  The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. , 2018, American heart journal.

[4]  J. Murnaghan,et al.  Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty , 2018, The New England journal of medicine.

[5]  S. E. Yeoh,et al.  Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. , 2017, The Cochrane database of systematic reviews.

[6]  Ajay Gupta,et al.  Embolic stroke of undetermined source: The role of the nonstenotic carotid plaque , 2017, Journal of the Neurological Sciences.

[7]  C. Kaymaz [EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism]. , 2017, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[8]  Deepak L. Bhatt,et al.  Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. , 2017, The Canadian journal of cardiology.

[9]  Tao Wu,et al.  Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis , 2017, Journal of Zhejiang University-SCIENCE B.

[10]  Yajing Zhang,et al.  The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis. , 2017, Clinical therapeutics.

[11]  J. Lekakis,et al.  Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role , 2017, Cardiovascular Drugs and Therapy.

[12]  Thalia Shoshana Field,et al.  Dabigatran following acute transient ischemic attack and minor stroke II (DATAS II) , 2017, International journal of stroke : official journal of the International Stroke Society.

[13]  M. Wolzt,et al.  Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients , 2017, Circulation. Heart failure.

[14]  A. Hardidge,et al.  Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty. , 2017, The Journal of arthroplasty.

[15]  G. Lip,et al.  Embolic Stroke of Undetermined Source and Detection of Atrial Fibrillation on Follow-Up: How Much Causality Is There? , 2016, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[16]  G. Lip,et al.  Risk Stratification for Recurrence and Mortality in Embolic Stroke of Undetermined Source , 2016, Stroke.

[17]  H. Kamel,et al.  Premature Atrial Contractions on the Screening Electrocardiogram and Risk of Ischemic Stroke: The Reasons for Geographic and Racial Differences in Stroke Study , 2016, Neuroepidemiology.

[18]  J. Pogue,et al.  Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial , 2016, European stroke journal.

[19]  H. Milionis,et al.  Embolic Strokes of Undetermined Source in the Athens Stroke Registry: An Outcome Analysis , 2015, Stroke.

[20]  H. Kamel,et al.  Left Atrial Enlargement and Stroke Recurrence: The Northern Manhattan Stroke Study , 2015, Stroke.

[21]  K. Vemmos,et al.  Embolic Strokes of Undetermined Source in the Athens Stroke Registry: A Descriptive Analysis , 2015, Stroke.

[22]  S. Connolly,et al.  Embolic strokes of undetermined source: the case for a new clinical construct , 2014, The Lancet Neurology.

[23]  Efstathios Manios,et al.  Association Between Obesity and Mortality After Acute First-Ever Stroke: The Obesity–Stroke Paradox , 2011, Stroke.

[24]  R. Meuli,et al.  The Acute STroke Registry and Analysis of Lausanne (ASTRAL): Design and Baseline Analysis of an Ischemic Stroke Registry Including Acute Multimodal Imaging , 2010, Stroke.

[25]  M. Hommel,et al.  Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. , 1994, The New England journal of medicine.

[26]  C. Duyckaerts,et al.  The prevalence of ulcerated plaques in the aortic arch in patients with stroke. , 1992, The New England journal of medicine.

[27]  Stroke: Highlights of Selected Articles. , 2017, Stroke.

[28]  R. Hart,et al.  Embolic Stroke. , 2017, Circulation.

[29]  K. Vemmos,et al.  Embolic Strokes of Undetermined Source in the Athens Stroke Registry A Descriptive Analysis , 2022 .